Sheffield based Siguru closes second seed to build AI for pharma compliance reviews
This article covers Siguru, an AI startup founded in May 2025, which has closed a second seed funding round to develop an AI system for medical, legal and regulatory review in the pharmaceutical sector. The funding is intended to validate market demand, improve a minimum viable product and hire staff as it prepares for commercial launch, targeting pharma marketing, medical affairs and governance teams to shorten MLR approval timelines.
Siguru, a Sheffield-founded AI startup, has closed a second seed funding round to further develop an AI system for medical, legal and regulatory review in the pharmaceutical sector. The founders say the fresh capital will be used to validate market demand, improve a minimum viable product and hire staff as the company prepares for a commercial launch.
Why it matters
Pharmaceutical marketing and medical affairs teams routinely face slow approval cycles for promotional and regulatory materials. Siguru says its platform targets the medical, legal and regulatory (MLR) review bottleneck, which it estimates can take up to 40 days today. Shortening that process could materially reduce time-to-market for campaigns and reduce operational overhead in highly regulated workflows.
Faster, more auditable reviews are particularly relevant as pharma companies invest in digital marketing and personalised content that still must pass tight compliance checks. Tools that combine natural language processing with workflow controls are becoming a common way for firms to reconcile speed with governance.
Inside the product
Siguru’s platform is positioned to support marketing and commercial teams, medical affairs, governance and digital functions by automating parts of the MLR review. The company says the system aims to accelerate approval timelines and embed compliance checks into existing pharma workflows.
The business is still pre-commercial and working on a minimum viable product. The founders plan product improvements, hires and partnership development as part of the next stage of go-to-market activity. No commercial customers or pilot partners were named in the announcement.
Who are the investors?
The founders say the round was raised through a mix of investors, friends, family and industry contacts; no lead investor or headline backers were disclosed. The company describes the funding as intended to support product development, validation of market demand and early hiring rather than an expanded sales roll-out at this stage.
If you're researching potential backers in this space:
- Explore our list of AI venture capital firms in the UK
- Browse our directory of AI angel investors in the UK
Founder perspective
Siguru was founded by Dan Bentley and Harry Bliss in May 2025. In the announcement, Harry Bliss, co-founder at Siguru, said:
We are an ambitious, high tech company at the forefront of AI technology-based systems.
Our products can be used by marketing and commercial teams, medical affairs and governance, digital teams, and leadership – anywhere approval speed and compliance both matter. The thriving online market offers high opportunities for growth.
Our AI platform supports pharma marketing and medical teams through the MLR process - aiming to reduce approval timelines from 40 days to a week.
Further development of the products and business through the funding will move us towards a commercial launch with the hiring of employees and improvements on a minimum viable product.
Siguru will expand through developing partnerships and go-to-market, working closely with medical and compliance leaders to build for real-world pharma workflows.
The bigger picture
The announcement sits within a broader trend of AI companies focusing on regulated industries, where automation can shave weeks off manual compliance workflows. For regional hubs such as Sheffield, early-stage AI businesses taking on regulated workflows demonstrate how talent outside London is building specialised enterprise tools.
The deal also reflects growing interest from AI investors in products that bring governance and explainability into operational processes, particularly in health and pharma sectors where regulatory risk is high.
As Siguru moves from prototype to pilot and hires its first staff, its progress will be one to watch for anyone tracking how AI is reshaping compliance and review processes across UK and European life sciences.
Click here for a full list of 7,589+ startup investors in the UK